Glenmark Pharmaceuticals has introduced a new over-the-counter (OTC) solution for constipation relief with the launch of polyethylene glycol 3350 powder in the US market. This treatment, available through Glenmark Therapeutics Inc., USA, offers the same strength as MiraLAX’s 17 grams per capful dosage.
Meeting the Growing Demand for Effective Solutions
By entering this segment, Glenmark aims to address the rising demand for OTC constipation treatments. Marc Kikuchi, Glenmark’s President & Business Head for North America, emphasized that the company’s expansion brings another supplier into the market, improving accessibility for consumers.
A Market Worth Over Half a Billion Dollars
According to Nielsen data for the 52 weeks ending February 22, 2025, the MiraLAX powder market recorded annual sales of approximately $555.7 million. This figure highlights the strong need for effective constipation relief solutions.
Commitment to Quality and Accessibility
With this launch, Glenmark reaffirms its dedication to delivering high-quality and affordable healthcare products. As reported by devdiscourse.com, the company continues to expand its portfolio to provide consumers with reliable treatment options.